CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 34 enrolled
Drug / intervention
2009 H1N1 Virus Vaccinebiological
Likely dose
2009 H1N1 Virus Vaccine 0.2 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01055184
NCT01055184Phase 2Completed
CompareCT.gov

Assessment of the Effect of Age on the Immunological and Virological Response to a Live Attenuated Influenza Vaccine for the 2009 H1N1 Virus

University of Rochester·interventional·Posted Jan 25, 2010·Updated May 30, 2016

In Brief

A Phase 2 clinical trial evaluating 2009 H1N1 Virus Vaccine for 2009 H1N1 Influenza Virus. Completed, enrolled 34 participants across 1 site.

Detailed Summary

Unlike most influenza viruses, the 2009 H1N1 virus has affected people between 5 and 40 years old more often than people 60 years old or older. It may be that older people have had greater exposure to previous strains of H1N1 influenza, and this previous exposure protects them from infection. This study will examine how older people respond to a version of the H1N1 virus vaccine that includes a live, noninfectious version of the virus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Conditions2009 H1N1 Influenza Virus
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH)

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 25, 2010
Enrollment StartMar 1, 2010
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 16.4 years ago

Interventions

2009 H1N1 Virus Vaccinebiological

Single 0.2 mL dose of live monovalent vaccine, delivered through nasal spray